Trinity Biotech Reports Q1 2026 Financial Results with Strong Demand for HIV Tests

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: 3 days ago

0mins

TRIB0%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

Strong Orders: Trinity Biotech has secured additional purchase orders for over 2 million units of its TrinScreen™ HIV rapid test, scheduled for fulfillment in Q3 2026, which is expected to significantly contribute to the company's revenue and profitability targets for 2026, reflecting robust demand for rapid HIV diagnostics in global health markets.
Improved Financial Performance: The company reported a 43% year-on-year revenue increase to $10.8 million in Q1 2026, primarily driven by a substantial rise in rapid HIV sales, particularly TrinScreen™ HIV, which surged from $0.4 million in Q1 2025 to $2.3 million, indicating enhanced market acceptance of its products.
Margin Enhancement: Gross margin improved from 25.2% to 35.4%, supported by operational restructuring under the Comprehensive Transformation Plan, with gross profit reaching $3.8 million compared to $1.9 million in Q1 2025, demonstrating significant progress in cost control and operational efficiency.
Strategic Transformation Plan: The ongoing Comprehensive Transformation Plan includes the outsourcing of UniGold HIV™ production, expected to be scaled up by Q3 2026, which will further enhance the company's EBITDA and cash flow generation capabilities, supporting its long-term growth strategy.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy TRIB?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on TRIB

About TRIB

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Trinity Biotech Reports Q1 2026 Earnings with Revenue Growth

2 days agoNASDAQ.COM

Significant Loss Reduction: Trinity Biotech reported a net loss of $4.39 million for Q1 2026, translating to a loss of $0.23 per share, which is a 50% decrease from last year's loss of $8.79 million or $0.48 per share, indicating progress in cost management.
Strong Revenue Growth: Total revenue for the first quarter reached $10.85 million, a 43% increase year-over-year, primarily driven by a surge in sales of Rapid HIV tests, which rose from $0.4 million last year to $3.7 million, reflecting a significant uptick in market demand.
Improved EBITDA: The EBITDA loss for this quarter was $1.95 million, considerably lower than the $5.84 million loss reported last year, while adjusted EBITDA showed a loss of $1.06 million, demonstrating enhanced operational efficiency.
Positive Future Outlook: The company anticipates completing over 2 million orders for its TrinScreen HIV tests in Q3 2026 and plans to scale up UniGold HIV commercially during the same quarter, aiming to improve gross margins and cash flow as part of its Comprehensive Transformation Plan.

Trinity Biotech Reports Q1 Financial Results with Improved Losses

3 days agoseekingalpha

Reduced Net Loss: Trinity Biotech reported a net loss of $4.4 million in Q1 2026, halving the loss from $8.8 million in Q1 2025, indicating improved financial management and operational efficiency.
Significant Revenue Growth: The company achieved revenue of $10.8 million in Q1, representing a 42.1% year-over-year increase, reflecting strong market demand and enhanced product sales, which bolsters future profitability potential.
Improved Adjusted EBITDA: The adjusted EBITDA for Q1 2026 was negative $1.1 million, a significant improvement from negative $4.0 million in Q1 2025, showcasing progress in operational efficiency and cost management.
Positive Financial Signals: Although still in a loss position, the improvements in net loss and EBITDA provide positive signals for investors, indicating that the company is making strides towards profitability, potentially attracting more investor interest.